tranexamic acid has been researched along with Disease Exacerbation in 17 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| "TICH-2 trial (Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage) was a randomized, placebo-controlled clinical trial recruiting acutely hospitalized participants with intracerebral hemorrhage within 8 hours after symptom onset." | 9.41 | Tranexamic Acid for Prevention of Hematoma Expansion in Intracerebral Hemorrhage Patients With or Without Spot Sign. ( Bath, PM; Christensen, H; Christensen, LM; Dineen, RA; Flaherty, K; Gluud, C; Jakobsen, JC; Law, Z; Overgaard, K; Ovesen, C; Rasmussen, RS; Sprigg, N; Steiner, T, 2021) |
| " Second, treatment of AD mice with the plasmin inhibitor tranexamic acid aggravated pathology, whereas removal of fibrinogen from the circulation of AD mice with ancrod treatment attenuated measures of neuroinflammation and vascular pathology." | 7.74 | Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. ( Melchor, JP; Paul, J; Strickland, S, 2007) |
| "Rationale Acute intracerebral hemorrhage inflicts a high-economic and -health burden." | 6.84 | Tranexamic acid for acute intracerebral hemorrhage growth predicted by spot sign trial: Rationale and design. ( Li, N; Liu, D; Liu, L; Meng, X; Nie, X; Tan, Y; Wang, Y; Zhao, X, 2017) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent, which has shown an effect on reducing blood loss in many diseases." | 6.72 | Tranexamic Acid Inhibits Hematoma Expansion in Intracerebral Hemorrhage and Traumatic Brain Injury. Does Blood Pressure Play a Potential Role? A Meta-Analysis from Randmized Controlled Trials. ( Chen, Z; Gao, B; Rong, X; Wang, Z; Xue, T; Yang, Y, 2021) |
| "TICH-2 trial (Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage) was a randomized, placebo-controlled clinical trial recruiting acutely hospitalized participants with intracerebral hemorrhage within 8 hours after symptom onset." | 5.41 | Tranexamic Acid for Prevention of Hematoma Expansion in Intracerebral Hemorrhage Patients With or Without Spot Sign. ( Bath, PM; Christensen, H; Christensen, LM; Dineen, RA; Flaherty, K; Gluud, C; Jakobsen, JC; Law, Z; Overgaard, K; Ovesen, C; Rasmussen, RS; Sprigg, N; Steiner, T, 2021) |
| " Second, treatment of AD mice with the plasmin inhibitor tranexamic acid aggravated pathology, whereas removal of fibrinogen from the circulation of AD mice with ancrod treatment attenuated measures of neuroinflammation and vascular pathology." | 3.74 | Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. ( Melchor, JP; Paul, J; Strickland, S, 2007) |
| "Rationale Acute intracerebral hemorrhage inflicts a high-economic and -health burden." | 2.84 | Tranexamic acid for acute intracerebral hemorrhage growth predicted by spot sign trial: Rationale and design. ( Li, N; Liu, D; Liu, L; Meng, X; Nie, X; Tan, Y; Wang, Y; Zhao, X, 2017) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent, which has shown an effect on reducing blood loss in many diseases." | 2.72 | Tranexamic Acid Inhibits Hematoma Expansion in Intracerebral Hemorrhage and Traumatic Brain Injury. Does Blood Pressure Play a Potential Role? A Meta-Analysis from Randmized Controlled Trials. ( Chen, Z; Gao, B; Rong, X; Wang, Z; Xue, T; Yang, Y, 2021) |
| "Tranexamic acid (TXA) has a time tested role in preventing poor outcomes linked to excessive haemorrhage in trauma patients." | 2.66 | Early tranexamic acid in traumatic brain injury: Evidence for an effective therapy. ( Bukhari, NS; Jooma, R, 2020) |
| "More than half of the patients felt that hereditary angioedema had a significant psychological impact on their lives and restricted their physical activities." | 1.40 | Hereditary angioedema - consequences of a new treatment paradigm in Denmark. ( Bygum, A, 2014) |
| "Treatment with tranexamic acid inhibited plasmin generation and abrogated enhanced AAA progression in pCPB(-/-) mice." | 1.36 | Enhanced abdominal aortic aneurysm formation in thrombin-activatable procarboxypeptidase B-deficient mice. ( Dalman, RL; Du, X; Leung, LL; Morser, J; Myles, T; Nishimura, T; Schultz, G; Sharif, S; Sho, E; Tedesco, MM, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 7 (41.18) | 2.80 |
| Authors | Studies |
|---|---|
| Law, ZK | 2 |
| Ali, A | 1 |
| Krishnan, K | 2 |
| Bischoff, A | 1 |
| Appleton, JP | 1 |
| Scutt, P | 1 |
| Woodhouse, L | 1 |
| Pszczolkowski, S | 1 |
| Cala, LA | 1 |
| Dineen, RA | 3 |
| England, TJ | 2 |
| Ozturk, S | 2 |
| Roffe, C | 2 |
| Bereczki, D | 2 |
| Ciccone, A | 1 |
| Christensen, H | 4 |
| Ovesen, C | 3 |
| Bath, PM | 4 |
| Sprigg, N | 4 |
| Bukhari, NS | 1 |
| Jooma, R | 1 |
| Walker, PF | 1 |
| Bozzay, JD | 1 |
| Johnston, LR | 1 |
| Elster, EA | 1 |
| Rodriguez, CJ | 1 |
| Bradley, MJ | 1 |
| Jiang, C | 1 |
| Wang, J | 2 |
| Zhang, J | 1 |
| Gao, B | 1 |
| Xue, T | 1 |
| Rong, X | 1 |
| Yang, Y | 1 |
| Wang, Z | 2 |
| Chen, Z | 1 |
| Desborough, M | 1 |
| Roberts, I | 1 |
| Al-Shahi Salman, R | 1 |
| Werring, DJ | 1 |
| Robinson, T | 1 |
| Dineen, R | 1 |
| Laska, AC | 1 |
| Peters, N | 1 |
| Egea-Guerrero, JJ | 1 |
| Karlinski, M | 1 |
| Thanabalan, J | 1 |
| Collins, R | 1 |
| Beridze, M | 1 |
| Jakobsen, JC | 2 |
| Gluud, C | 2 |
| Steiner, T | 2 |
| Law, Z | 2 |
| Flaherty, K | 2 |
| Christensen, LM | 1 |
| Overgaard, K | 1 |
| Rasmussen, RS | 1 |
| Liu, L | 1 |
| Wang, Y | 1 |
| Meng, X | 1 |
| Li, N | 1 |
| Tan, Y | 1 |
| Nie, X | 1 |
| Liu, D | 1 |
| Zhao, X | 1 |
| Wen, KC | 1 |
| Sung, PL | 1 |
| Chou, YT | 1 |
| Pan, CM | 1 |
| Wang, PH | 1 |
| Lee, OK | 1 |
| Wu, CW | 1 |
| Bygum, A | 1 |
| Asero, R | 1 |
| Tedeschi, A | 1 |
| Cugno, M | 1 |
| Schultz, G | 1 |
| Tedesco, MM | 1 |
| Sho, E | 1 |
| Nishimura, T | 1 |
| Sharif, S | 1 |
| Du, X | 1 |
| Myles, T | 1 |
| Morser, J | 1 |
| Dalman, RL | 1 |
| Leung, LL | 1 |
| Riddell, A | 1 |
| Abdul-Kadir, R | 1 |
| Pollard, D | 1 |
| Tuddenham, E | 1 |
| Gomez, K | 1 |
| Amarapurkar, DN | 1 |
| Patel, ND | 1 |
| Paul, J | 1 |
| Strickland, S | 1 |
| Melchor, JP | 1 |
| Meijer, K | 1 |
| Smid, WM | 1 |
| Geerards, S | 1 |
| van der Meer, J | 1 |
2 reviews available for tranexamic acid and Disease Exacerbation
| Article | Year |
|---|---|
Early tranexamic acid in traumatic brain injury: Evidence for an effective therapy.
Topics: Antifibrinolytic Agents; Brain Contusion; Brain Hemorrhage, Traumatic; Brain Injuries, Traumatic; Di | 2020 |
Tranexamic Acid Inhibits Hematoma Expansion in Intracerebral Hemorrhage and Traumatic Brain Injury. Does Blood Pressure Play a Potential Role? A Meta-Analysis from Randmized Controlled Trials.
Topics: Antifibrinolytic Agents; Brain Hemorrhage, Traumatic; Cerebral Hemorrhage; Disease Progression; Hema | 2021 |
4 trials available for tranexamic acid and Disease Exacerbation
| Article | Year |
|---|---|
Rationale and Design of a Randomized, Double-Blind Trial Evaluating the Efficacy of Tranexamic Acid on Hematoma Expansion and Peri-hematomal Edema in Patients with Spontaneous Intracerebral Hemorrhage within 4.5 h after Symptom Onset: The THE-ICH Trial Pr
Topics: Antifibrinolytic Agents; Brain Edema; Cerebral Hemorrhage; China; Disease Progression; Double-Blind | 2020 |
Tranexamic Acid for Prevention of Hematoma Expansion in Intracerebral Hemorrhage Patients With or Without Spot Sign.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Cerebral Angiography; Cerebral Hemorrhage; Compute | 2021 |
Tranexamic acid for acute intracerebral hemorrhage growth predicted by spot sign trial: Rationale and design.
Topics: Antifibrinolytic Agents; Brain; Cerebral Hemorrhage; Disease Progression; Humans; Research Design; T | 2017 |
Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial.
Topics: Antifibrinolytic Agents; Cerebral Hemorrhage; Data Interpretation, Statistical; Disease Progression; | 2018 |
11 other studies available for tranexamic acid and Disease Exacerbation
| Article | Year |
|---|---|
Noncontrast Computed Tomography Signs as Predictors of Hematoma Expansion, Clinical Outcome, and Response to Tranexamic Acid in Acute Intracerebral Hemorrhage.
Topics: Aged; Cerebral Hemorrhage; Cohort Studies; Disease Progression; Female; Hematoma; Humans; Logistic M | 2020 |
Outcomes of tranexamic acid administration in military trauma patients with intracranial hemorrhage: a cohort study.
Topics: Adult; Antifibrinolytic Agents; Disease Progression; Female; Glasgow Outcome Scale; Humans; Intracra | 2020 |
Outcomes in Antiplatelet-Associated Intracerebral Hemorrhage in the TICH-2 Randomized Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Cerebral Hemorrhage; Disease Progression; Dose-Response Relationship, | 2021 |
The role of EpCAM in tumor progression and the clinical prognosis of endometrial carcinoma.
Topics: Animals; Antifibrinolytic Agents; Cell Line, Tumor; Disease Progression; Down-Regulation; Endometria | 2018 |
Hereditary angioedema - consequences of a new treatment paradigm in Denmark.
Topics: Activities of Daily Living; Administration, Cutaneous; Adult; Aged; Angioedemas, Hereditary; Bradyki | 2014 |
Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Cetirizine; Chr | 2010 |
Enhanced abdominal aortic aneurysm formation in thrombin-activatable procarboxypeptidase B-deficient mice.
Topics: Animals; Antifibrinolytic Agents; Aortic Aneurysm, Abdominal; Aortic Rupture; Apolipoproteins E; Car | 2010 |
Monitoring low dose recombinant factor VIIa therapy in patients with severe factor XI deficiency undergoing surgery.
Topics: Abdomen; Adult; Antifibrinolytic Agents; Cesarean Section; Cholecystectomy; Disease Progression; Dru | 2011 |
Gastric antral vascular ectasia (GAVE) syndrome.
Topics: Aged; Anemia, Iron-Deficiency; Chronic Disease; Disease Progression; Female; Gastric Antral Vascular | 2004 |
Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Disease Models, Animal; Disease Progression; Fibrin | 2007 |
Hyperfibrinogenolysis in disseminated adenocarcinoma.
Topics: Adenocarcinoma; Adult; Afibrinogenemia; alpha-2-Antiplasmin; Antifibrinolytic Agents; Brain Ischemia | 1998 |